Development of a workflow for in vitro on- and off-target cytotoxicity assessment of CAR T cell therapies to support first-in-human clinical trials: An orthogonal approach using human induced pluripotent stem cell-derived cells as a surrogate for normal vital organ systems.

开发用于体外评估 CAR T 细胞疗法靶向和非靶向细胞毒性的工作流程，以支持首次人体临床试验：采用正交方法，利用人类诱导多能干细胞衍生的细胞作为正常重要器官系统的替代物